heart disease

AstraZeneca's Brilinta Fails to Win FDA Approval

AstraZeneca failed to win FDA approval for its potential heart drug Brilinta, a drug the company -- which is about to face a severe patent cliff -- had high hopes for. Shares in the U.K. drugmaker dropped in London and were over 5% lower in premarket trading in New York.

Health Reform Leaves Millions Uninsured

While many politicians trumpet the increased insurance coverage in the health-reform legislation, the bill the Senate will soon vote on still leaves 23 million uninsured. What's more, neither the Senate nor the House version of the reform takes effect before 2013, leaving many uninsured without relief for years.

Crestor Backed by FDA for Patients With Normal Cholesterol

AstraZeneca scored a win on Tuesday, when a Food and Drug Administration advisory panel recommended broader use of Crestor, the company's cholesterol-lowering drug. The panel recommended that those with low cholesterol use the drug, following studies finding that Crestor reduces the risk of heart disease even in those with normal cholesterol levels.